Compare BAND & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | RGNX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 418.1M |
| IPO Year | 2017 | 2015 |
| Metric | BAND | RGNX |
|---|---|---|
| Price | $17.91 | $8.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $20.40 | ★ $28.75 |
| AVG Volume (30 Days) | 404.0K | ★ 741.4K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | $10,393,000.00 |
| Revenue This Year | $15.34 | $50.05 |
| Revenue Next Year | $7.89 | $23.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 126.48 |
| 52 Week Low | $11.33 | $5.04 |
| 52 Week High | $18.63 | $16.19 |
| Indicator | BAND | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 48.10 |
| Support Level | $14.98 | $7.81 |
| Resistance Level | $18.63 | $9.28 |
| Average True Range (ATR) | 0.83 | 0.46 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 85.77 | 68.66 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.